Sarepta Therapeutics Inc (SRPT) Stake Boosted by Chicago Equity Partners LLC

Chicago Equity Partners LLC grew its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 39.8% in the 3rd quarter, Holdings Channel reports. The fund owned 24,230 shares of the biotechnology company’s stock after buying an additional 6,895 shares during the quarter. Chicago Equity Partners LLC’s holdings in Sarepta Therapeutics were worth $3,913,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. IFP Advisors Inc raised its stake in shares of Sarepta Therapeutics by 40.2% during the third quarter. IFP Advisors Inc now owns 1,654 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 474 shares during the last quarter. Xact Kapitalforvaltning AB raised its stake in shares of Sarepta Therapeutics by 5.7% during the second quarter. Xact Kapitalforvaltning AB now owns 9,202 shares of the biotechnology company’s stock valued at $1,216,000 after acquiring an additional 500 shares during the last quarter. BB&T Corp increased its position in shares of Sarepta Therapeutics by 16.9% during the third quarter. BB&T Corp now owns 3,487 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 504 shares during the period. Principal Financial Group Inc. increased its position in shares of Sarepta Therapeutics by 2.7% during the first quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock valued at $1,478,000 after buying an additional 530 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its position in shares of Sarepta Therapeutics by 0.5% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 145,854 shares of the biotechnology company’s stock valued at $19,279,000 after buying an additional 709 shares during the period. 89.84% of the stock is owned by hedge funds and other institutional investors.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $140.50, for a total value of $936,713.50. Following the sale, the director now owns 126,534 shares in the company, valued at $17,778,027. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Sandesh Mahatme sold 107,524 shares of the company’s stock in a transaction dated Wednesday, October 24th. The stock was sold at an average price of $127.74, for a total transaction of $13,735,115.76. Following the completion of the sale, the chief financial officer now owns 48,381 shares in the company, valued at approximately $6,180,188.94. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.

Shares of SRPT opened at $133.00 on Friday. The stock has a market capitalization of $9.17 billion, a price-to-earnings ratio of -81.10 and a beta of 1.59. The company has a debt-to-equity ratio of 0.65, a quick ratio of 7.84 and a current ratio of 8.85. Sarepta Therapeutics Inc has a fifty-two week low of $50.51 and a fifty-two week high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.29). The business had revenue of $78.49 million during the quarter, compared to analysts’ expectations of $78.84 million. Sarepta Therapeutics had a negative return on equity of 23.67% and a negative net margin of 89.46%. As a group, equities analysts predict that Sarepta Therapeutics Inc will post -4.38 earnings per share for the current year.

Several equities analysts recently issued reports on the stock. Citigroup boosted their price target on shares of Sarepta Therapeutics from $174.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday. BidaskClub cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 31st. Piper Jaffray Companies reduced their price target on shares of Sarepta Therapeutics from $189.00 to $168.00 and set an “overweight” rating on the stock in a research report on Friday, October 26th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $147.00 price target on the stock in a research report on Tuesday, October 16th. Finally, Sanford C. Bernstein assumed coverage on shares of Sarepta Therapeutics in a research report on Friday, October 12th. They set an “outperform” rating and a $170.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, twenty-four have given a buy rating and one has issued a strong buy rating to the company. Sarepta Therapeutics has an average rating of “Buy” and an average price target of $169.19.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.wkrb13.com/2018/11/09/sarepta-therapeutics-inc-srpt-stake-boosted-by-chicago-equity-partners-llc.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Featured Article: Stock Symbol

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply